| Identification | Back Directory | [Name]
L-Alaninamide, N-[10,10-dioxido-1,12-dioxo-14-[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-yl]-3,6,13-trioxa-10-thia-9,11-diazatetradec-1-yl]-L-valyl-N-[4-[[[[(11S,11aS)-8-[[5-[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]oxy]methyl]phenyl]- | [CAS]
2126805-05-6 | [Synonyms]
L-Alaninamide, N-[10,10-dioxido-1,12-dioxo-14-[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-yl]-3,6,13-trioxa-10-thia-9,11-diazatetradec-1-yl]-L-valyl-N-[4-[[[[(11S,11aS)-8-[[5-[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7...
L-Alaninamide, N-[10,10-dioxido-1,12-dioxo-14-[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-yl]-3,6,13-trioxa-10-thia-9,11-diazatetradec-1-yl]-L-valyl-N-[4-[[[[(11S,11aS)-8-[[5-[[(11aS)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1H-pyrrolo[2,1-c][1,4]benzodiazepin-10(5H)-yl]carbonyl]oxy]methyl]phenyl]- | [Molecular Formula]
C66H83N9O18S | [MOL File]
2126805-05-6.mol | [Molecular Weight]
1322.48 |
| Hazard Information | Back Directory | [Uses]
BCN-HS-PEG2-VA-PABC-SG3199 (Compound 4) is a pyrrolobenzodiazepine that can be used as a agent linker of antibody-drug conjugates (ADC)[1]. BCN-HS-PEG2-VA-PABC-SG3199 is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. | [References]
[1] Patricius Hendrikus Cornelis VAN BERKEL. Pyrrolobenzodiazepine-antibody conjugates. Patent WO2018146199A1. |
|
|